Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 21, Issue 2, 2005, Pages 37-41

  Kinoshita, Yoshikazu ^a   Hashimoto, T ^b   Kawamura, A ^c   Yuki, M ^d   Amano, K ^e   Sato, H ^f   Adachi, K ^a   Sato, S ^a   Oshima, N ^a   Takashima, T ^g   Kitajima, N ^g   Abe, K ^f   Suetsugu, H ^b  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b Unnan General Hospital   (Japan)

^c Ono Municipal Hospital   (Japan)

^d Hirata Municipal Hospital   (Japan)

^e Masuda Red Cross General Hospital   (Japan)

^f Ohda Municipal Hospital   (Japan)

^g Kasai Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; MOSAPRIDE CITRATE; TANDOSPIRONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 20444406090     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02472.x     Document Type: Article

References (13)

1. Talley NJ, Stangheilini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42.
2. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55.
3. Talley NJ, McNeil D, Hayden A, Piper DW. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986; 91: 149-56.
4. Farup PG, Wetterhus S, Osnes M, Ulshageri K. Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997; 32: 755-9.
5. Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. Scand J Gastroenterol 1994; 29: 618-23.
6. Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 1291-9.
7. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
8. Hirakawa K, Adachi K, Amano K, et al. Prevalence of nonulcer dyspepsia in the Japanese population. J Gastroenterol Hepatol 1999; 14: 1083-7.
9. Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004; 2: 985-96.
10. Chen SY, Wang JY, Zhu CW, et al. A randomized controlled Multi-center clinical trial on mosapride in the treatment of functional dyspepsia. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 165-8.
11. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002; 16: 1641-8.
12. Mearin F, Rodrigo L, Perez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized: double-masked trial. Clin Gastroenterol Hepatol 2004; 2: 301-8.
13. Tack J, Broekaert D, Coulie B, Fischler B, Janssens J. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003; 17: 603-8.